220 related articles for article (PubMed ID: 11823973)
21. Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas.
Diebold J; Deisenhofer I; Baretton GB; Blasenbreu S; Suchy B; Schneiderbanger K; Meier W; Haas CJ; Löhrs U
Lab Invest; 1996 Oct; 75(4):473-85. PubMed ID: 8874380
[TBL] [Abstract][Full Text] [Related]
22. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
23. Genomic imbalances in ovarian borderline serous and mucinous tumors.
Hu J; Khanna V; Jones MM; Surti U
Cancer Genet Cytogenet; 2002 Nov; 139(1):18-23. PubMed ID: 12547152
[TBL] [Abstract][Full Text] [Related]
24. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
Staebler A; Karberg B; Behm J; Kuhlmann P; Neubert U; Schmidt H; Korsching E; Bürger H; Lelle R; Kiesel L; Böcker W; Shih IeM; Buchweitz O
Genes Chromosomes Cancer; 2006 Oct; 45(10):905-17. PubMed ID: 16845658
[TBL] [Abstract][Full Text] [Related]
25. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
28. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
29. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
30. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.
Bell KA; Smith Sehdev AE; Kurman RJ
Am J Surg Pathol; 2001 Apr; 25(4):419-32. PubMed ID: 11257616
[TBL] [Abstract][Full Text] [Related]
31. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53.
Katabuchi H; Tashiro H; Cho KR; Kurman RJ; Hedrick Ellenson L
Int J Gynecol Pathol; 1998 Jan; 17(1):54-60. PubMed ID: 9475193
[TBL] [Abstract][Full Text] [Related]
32. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
33. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
34. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis.
Pere H; Tapper J; Seppälä M; Knuutila S; Butzow R
Cancer Res; 1998 Oct; 58(19):4274-6. PubMed ID: 9766651
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis.
Hu J; Khanna V; Jones MW; Surti U
Gynecol Oncol; 2003 Jun; 89(3):369-75. PubMed ID: 12798697
[TBL] [Abstract][Full Text] [Related]
36. Genomic profile of ovarian carcinomas.
Micci F; Haugom L; Abeler VM; Davidson B; Tropé CG; Heim S
BMC Cancer; 2014 May; 14():315. PubMed ID: 24886194
[TBL] [Abstract][Full Text] [Related]
37. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
[TBL] [Abstract][Full Text] [Related]
38. Metaplastic papillary tumor of the salpinx: report of a case using microsatellite analysis.
D'Adda T; Pizzi S; Bottarelli L; Azzoni C; Manni S; Giordano G
Int J Gynecol Pathol; 2011 Nov; 30(6):532-5. PubMed ID: 21979587
[TBL] [Abstract][Full Text] [Related]
39. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas.
Sonoda G; Palazzo J; du Manoir S; Godwin AK; Feder M; Yakushiji M; Testa JR
Genes Chromosomes Cancer; 1997 Dec; 20(4):320-8. PubMed ID: 9408747
[TBL] [Abstract][Full Text] [Related]
40. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
